Patient Characteristics and Peripheral Blood Responses to GM-CSF (Acquired PAP)
| Patient No. . | Duration GM-CSF (d) . | Mean Daily Dose (day 1-21) (μg/kg)/(μg/m2) . | Baseline Cell Counts (×109/L) . | Peak Cell Counts Before Day 21 (×109/L) . | ||||
|---|---|---|---|---|---|---|---|---|
| Total WBC . | Neutrophils . | Eosinophils . | Total WBC . | Neutrophils . | Eosinophils . | |||
| 1 (course no. 1)* | 70 | 3.8/166 | 6.5 | 3.9 | 0.20 | 8.7 | 6.0 | 0.57 |
| 1 (course no. 2)* | 264 | 3.8/168 | 5.9 | 3.3 | 0.18 | 8.3 | 5.4 | 0.76 |
| 2 | 42 | 4.6/164 | 7.2 | 3.8 | 0.12 | 5.5 | 3.3 | 0.20 |
| 3-151 | 170 | 4.3/180-152 | 6.8 | 4.3 | 0.05 | 6.7 | 4.3 | 0.08 |
| 4 | 13 | 4.1/147-153 | 4.8 | 2.2 | 0.10 | 6.0 | 2.6 | 0.24 |
| 5 | 42 | 4.7/210 | 4.6 | 2.4 | 0.06 | 6.1 | 3.4 | 0.20 |
| 6¶ | 37 | 4.5/167 | 6.7 | 4.3 | 0.17 | 6.5 | 4.5 | 0.35 |
| 7 | 42 | 4.6/185 | 7.4 | 4.5 | 0.09 | 8.2 | 5.4 | 0.13 |
| 8¶ | 84 | 5.8/229 | 5.4 | 2.9 | 0.09 | 5.4 | 3.0 | 0.59 |
| 9 | 84 | 4.2/168 | 5.1 | 3.2 | 0.03 | 6.8 | 5.2 | 0.41 |
| 10 | 84 | 4.4/169 | 8.6 | 4.8 | 0.13 | 8.4 | 5.9 | 0.41 |
| 11 | 84 | 4.7/168 | 5.5 | 3.8 | 0.01 | 5.9 | 4.4 | 0.12 |
| 12¶ | 21+ | 4.5/204 | 6.8 | 3.9 | 0.07 | 7.4 | 4.3 | 0.28 |
| Mean (SD) | 71 (51) | 4.5 (0.5)/180 (23) | 6.3 (1.2) | 3.6 (0.8) | 0.09 (0.05) | 6.8 (1.1) | 4.3 (1.1) | 0.31 (0.18) |
| Patient No. . | Duration GM-CSF (d) . | Mean Daily Dose (day 1-21) (μg/kg)/(μg/m2) . | Baseline Cell Counts (×109/L) . | Peak Cell Counts Before Day 21 (×109/L) . | ||||
|---|---|---|---|---|---|---|---|---|
| Total WBC . | Neutrophils . | Eosinophils . | Total WBC . | Neutrophils . | Eosinophils . | |||
| 1 (course no. 1)* | 70 | 3.8/166 | 6.5 | 3.9 | 0.20 | 8.7 | 6.0 | 0.57 |
| 1 (course no. 2)* | 264 | 3.8/168 | 5.9 | 3.3 | 0.18 | 8.3 | 5.4 | 0.76 |
| 2 | 42 | 4.6/164 | 7.2 | 3.8 | 0.12 | 5.5 | 3.3 | 0.20 |
| 3-151 | 170 | 4.3/180-152 | 6.8 | 4.3 | 0.05 | 6.7 | 4.3 | 0.08 |
| 4 | 13 | 4.1/147-153 | 4.8 | 2.2 | 0.10 | 6.0 | 2.6 | 0.24 |
| 5 | 42 | 4.7/210 | 4.6 | 2.4 | 0.06 | 6.1 | 3.4 | 0.20 |
| 6¶ | 37 | 4.5/167 | 6.7 | 4.3 | 0.17 | 6.5 | 4.5 | 0.35 |
| 7 | 42 | 4.6/185 | 7.4 | 4.5 | 0.09 | 8.2 | 5.4 | 0.13 |
| 8¶ | 84 | 5.8/229 | 5.4 | 2.9 | 0.09 | 5.4 | 3.0 | 0.59 |
| 9 | 84 | 4.2/168 | 5.1 | 3.2 | 0.03 | 6.8 | 5.2 | 0.41 |
| 10 | 84 | 4.4/169 | 8.6 | 4.8 | 0.13 | 8.4 | 5.9 | 0.41 |
| 11 | 84 | 4.7/168 | 5.5 | 3.8 | 0.01 | 5.9 | 4.4 | 0.12 |
| 12¶ | 21+ | 4.5/204 | 6.8 | 3.9 | 0.07 | 7.4 | 4.3 | 0.28 |
| Mean (SD) | 71 (51) | 4.5 (0.5)/180 (23) | 6.3 (1.2) | 3.6 (0.8) | 0.09 (0.05) | 6.8 (1.1) | 4.3 (1.1) | 0.31 (0.18) |
*Results from the two treatment courses in patient no. 1 are averaged for the overall analysis.
Patient developed a grade 2 febrile reaction to GM-CSF on day 20 leading to the withdrawal of GM-CSF for 8 days. This reaction was treated with a single dose of intravenous hydrocortisone (100 mg) resulting in a leukocytosis of 11.1 × 109/L, with a neutrophil count of 10.0 × 109/L 48 hours later. Because these changes were most likely attributable to the corticosteroid, peripheral blood counts from days 21 and 22 were excluded from the above-noted analyses.
Data from the first 20 days of treatment only (see * note above).
Data from 13 days of treatment only.
¶These patients were treated with yeast-derived recombinant GM-CSF (Leukine; Immunex); all other patients received bacterially synthesized recombinant GM-CSF (Leucomax; Schering-Plough).